| Literature DB >> 28902930 |
Q-L Gu1, Y Han2, Y-M Lan1, Y Li3, W Kou1, Y-S Zhou1, X-J Hai1, B Yan1, C-H Ci1.
Abstract
We investigated the influence of apolipoprotein B gene (APOB) variants on the risk of hyperlipidemia (HL) in 631 middle-aged and elderly members of the Chinese Yugur population (HL, n=336; normolipidemia, n=295). APOB polymorphisms were identified using mass spectrometry, and five single nucleotide polymorphisms (rs1042034, rs2163204, rs512535, rs676210, and rs679899) and serum lipids were further analyzed. rs1042034 and rs676210 were significantly associated with HL (P<0.05). Compared with the GG or AA genotype, individuals with AG and AG+AA in rs1042034 and with AG and AG+GG in rs676210 had a 1.67-fold (95%CI=1.20-2.33),1.63-fold (95%CI=1.19-2.24), 1.72-fold (95%CI=1.24-2.40), and 1.67-fold (95%CI=1.21-2.291) increased risk of high HL, respectively. rs2163204 was in strong linkage disequilibrium with rs1042034, rs676210, and rs679899, and strong disequilibrium was observed between rs1042034 and rs676210 (D'>0.9). Compared with the GTGAA haplotype, haplotypes ATGGA and ATAGG were more strongly associated with HL [odds ratio (OR)=1.46, 95%CI=0.02-2.11; OR=1.63, 95%CI=1.03-2.60, respectively]. The risk factors age (P=0.008), body mass index (P<0.0001), GA+GG genotype in rs676210 (P=0.009), and alcohol consumption (P=0.056) contributed strongly to HL development. The A allele of rs1042034 and the G allele of rs676210 may thus predispose middle-aged and elderly members of the Chinese Yugur population to HL in combination with other genetic or nutritional factors, and could be used as new genetic markers for HL screening.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28902930 PMCID: PMC5597288 DOI: 10.1590/1414-431X20176613
Source DB: PubMed Journal: Braz J Med Biol Res ISSN: 0100-879X Impact factor: 2.590
Characteristics of the study population.
| Normolipidemia (n=295) | Hyperlipidemia (n=336) | P-value | |
|---|---|---|---|
| Male gender (%) | 41.02 | 45.24 | 0.286 |
| Age (years) | 52.31±8.83 | 54.24±9.35 | 0.008 |
| BMI (kg/m2) | 23.24±2.61 | 24.37±3.15 | <0.001 |
| SBP (mmHg) | 117.07±10.61 | 118.77±10.51 | 0.044 |
| DBP (mmHg) | 77.87±6.18 | 78.64±5.36 | 0.018 |
| Total cholesterol (mM) | 3.52±0.77 | 4.25±1.24 | <0.001 |
| Triglycerides (mM) | 1.24±0.43 | 2.36±1.33 | <0.001 |
| HDLc (mM) | 1.22±0.23 | 1.09±0.42 | <0.001 |
| LDLc (mM) | 1.87±0.62 | 2.12±0.93 | <0.001 |
| Blood glucose (mM) | 4.62±1.06 | 4.74±1.14 | 0.009 |
| Smoker (%) | 23.05 | 27.98 | 0.005 |
| Drinking (%) | 23.39 | 31.25 | 0.006 |
Data are reported as means±SD or percentage. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HDLc: high-density lipoprotein cholesterol; LDLc: low-density lipoprotein cholesterol. Statistical analysis was carried out with Student's t-test and the chi-square test.
Genotypic associations of five SNPs with hyperlipidemia.
| SNP | Model | Genotype | Controls | Cases | OR (95%CI) | P-value |
|---|---|---|---|---|---|---|
| rs1042034 | – | – | n=295 | n=335 | – | – |
| P(HWE) | – | 0.275 | 0.219 | – | – | |
| Co-dominant | G/G | 175 (59.3%) | 158 (47.2%) | 1 | 0.009 | |
| A/G | 100 (33.9%) | 151 (45.1%) | 1.67 (1.20–2.33) | |||
| A/A | 20 (6.8%) | 26 (7.8%) | 1.44 (0.77–2.68) | |||
| Dominant | G/G | 175 (59.3%) | 158 (47.2%) | 1 | 0.002 | |
| A/G-A/A | 120 (40.7%) | 177 (52.8%) | 1.63 (1.19–2.24) | |||
| Recessive | G/G-A/G | 275 (93.2%) | 309 (92.2%) | 1 | 0.64 | |
| A/A | 20 (6.8%) | 26 (7.8%) | 1.16 (0.63–2.12) | |||
| rs2163204 | – | – | n=295 | n=336 | – | – |
| P(HWE) | – | 0.100 | 0.210 | – | – | |
| Co-dominant | T/T | 238 (80.7%) | 274 (81.5%) | 1 | 0.50 | |
| G/T | 57 (19.3%) | 61 (18.1%) | 0.93 (0.62–1.39) | |||
| G/G | 0 (0%) | 1 (0.3%) | NA (0.00-NA) | |||
| Dominant | T/T | 238 (80.7%) | 274 (81.5%) | 1 | 0.78 | |
| G/T-G/G | 57 (19.3%) | 62 (18.4%) | 0.94 (0.63–1.41) | |||
| Recessive | T/T-G/T | 295 (100%) | 335 (99.7%) | 1 | 0.26 | |
| G/G | 0 (0%) | 1 (0.3%) | NA (0.00-NA) | |||
| rs512535 | – | – | n=295 | n=336 | – | – |
| P(HWE) | – | 0.530 | 0.566 | – | – | |
| Co-dominant | G/G | 151 (51.2%) | 180 (53.6%) | 1 | 0.79 | |
| A/G | 117 (39.7%) | 129 (38.4%) | 0.92 (0.66–1.29) | |||
| A/A | 27 (9.2%) | 27 (8%) | 0.84 (0.47–1.49) | |||
| Dominant | G/G | 151 (51.2%) | 180 (53.6%) | 1 | 0.55 | |
| A/G-A/A | 144 (48.8%) | 156 (46.4%) | 0.91 (0.66–1.24) | |||
| Recessive | G/G-A/G | 268 (90.8%) | 309 (92%) | 1 | 0.62 | |
| A/A | 27 (9.2%) | 27 (8%) | 0.87 (0.50–1.52) | |||
| rs676210 | – | n=295 | n=336 | – | – | |
| P(HWE) | – | 0.241 | 0.143 | – | – | |
| Co-dominant | A/A | 176 (59.7%) | 158 (47%) | 1 | 0.005 | |
| G/A | 99 (33.6%) | 153 (45.5%) | 1.72 (1.24–2.40) | |||
| G/G | 20 (6.8%) | 25 (7.4%) | 1.39 (0.74–2.60) | |||
| Dominant | A/A | 176 (59.7%) | 158 (47%) | 1 | 0.002 | |
| G/A-G/G | 119 (40.3%) | 178 (53%) | 1.67 (1.21–2.29) | |||
| Recessive | A/A-G/A | 275 (93.2%) | 311 (92.6%) | 1 | 0.75 | |
| G/G | 20 (6.8%) | 25 (7.4%) | 1.11 (0.60–2.03) | |||
| rs679899 | – | – | n=295 | n=336 | – | – |
| P(HWE) | – | 0.329 | 0.936 | – | – | |
| Co-dominant | A/A | 197 (66.8%) | 214 (63.7%) | 1 | 0.66 | |
| G/A | 85 (28.8%) | 108 (32.1%) | 1.17 (0.83–1.65) | |||
| G/G | 13 (4.4%) | 14 (4.2%) | 0.99 (0.45–2.16) | |||
| Dominant | A/A | 197 (66.8%) | 214 (63.7%) | 1 | 0.42 | |
| G/A-G/G | 98 (33.2%) | 122 (36.3%) | 1.15 (0.82–1.59) | |||
| Recessive | A/A-G/A | 282 (95.6%) | 322 (95.8%) | 1 | 0.88 | |
| G/G | 13 (4.4%) | 14 (4.2%) | 0.94 (0.44–2.04) |
SNP: single nucleotide polymorphism; OR: odds ratio; CI: confidence interval; HWE: Hardy-Weinberg equilibrium; NA: not applicable.
Standardized linkage disequilibrium coefficients (D′) among five apolipoprotein B gene single nucleotide polymorphisms (SNP).
| SNP | rs1042034 | rs2163204 | rs512535 | rs676210 | rs679899 |
|---|---|---|---|---|---|
| rs1042034 | – | 0.997/0.001 | 0.130/0.0001 | 0.991/0.0001 | 0.438/0.0001 |
| rs2163204 | -0.197 | – | 0.806/0.0001 | 0.997/0.001 | 0.996/0.002 |
| rs512535 | 0.127 | 0.419 | – | 0.132/0.0001 | 0.719/0.0001 |
| rs676210 | 0.988 | -0.197 | 0.129 | – | 0.434/0.0001 |
| rs679899 | 0.354 | -0.159 | 0.568 | 0.351 | – |
The upper diagonal values are D′/P, and the lower diagonal values are the correlation coefficients (r).
Strong linkage disequilibrium.
Haplotype analyses between the two study groups.
| Haplotype | Total frequency (%) | Control frequency (%) | Case frequency (%) | P | OR | 95%CI |
|---|---|---|---|---|---|---|
| GTGAA | 51.93 | 50.85 | 53.57 | – | – | |
| ATGGA | 14.38 | 16.30 | 11.86 | 0.04 | 1.46 | 0.02–2.11 |
| ATAGG | 8.28 | 9.88 | 6.59 | 0.04 | 1.63 | 1.03–2.60 |
| GGAAA | 8.26 | 7.82 | 8.46 | 0.67 | 0.91 | 0.59–1.41 |
| GTAAG | 7.29 | 6.40 | 8.20 | 0.47 | 0.84 | 0.52–1.35 |
| ATGGG | 3.17 | 3.09 | 3.20 | 0.84 | 1.08 | 0.54–2.13 |
| GTAAA | 3.08 | 2.27 | 4.05 | 0.22 | 0.63 | 0.30–1.32 |
| GGGAA | 1.24 | 1.50 | 0.94 | 0.28 | 1.85 | 0.61–5.65 |
| ATAGA | 1.10 | 0.88 | 1.31 | 0.55 | 0.66 | 0.16–2.62 |
| Rare | 1.27 | 1.01 | 1.82 | 0.30 | 0.54 | 0.17–1.73 |
In the order of rs1042034, rs2163204, rs512535, rs676210, and rs679899. OR: odds ratio; CI: confidence interval.
Multivariate regression results of hyperlipidemia pathogenic factors.
| Variables | (B) | Wals | P-value | Exp(B) |
|---|---|---|---|---|
| Age (mean, years) | 0.198 | 4.593 | 0.032 | 1.219 |
| BMI (kg/m2) | 0.570 | 17.873 | <0.0001 | 1.779 |
| Systolic blood pressure (mmHg) | −0.034 | 0.036 | 0.849 | 0.966 |
| Diastolic blood pressure (mmHg) | 0.191 | 0.458 | 0.498 | 1.210 |
| Blood glucose (mg/dL) | 0.113 | 0.184 | 0.668 | 1.119 |
| Smoker | −0.199 | 0.337 | 0.562 | 0.819 |
| Drinker | 0.369 | 3.652 | 0.056 | 1.446 |
| rs1042034: AG+AA | −0.712 | 0.330 | 0.566 | 0.491 |
| rs676210: GA+GG | 0.450 | 6.865 | 0.009 | 1.569 |
Variables allowed to enter the model were those with P<0.20 in the binary logistic regression analysis. BMI: body mass index.